aluxum
- 10x Genomics (NASDAQ:TXG) is up 10% in Thursday morning trading after Street firm reacted positively to the company's Q4 2022 results and 2023 guidance.
- The life science technology company beat on the top and bottom lines.
- While 10x Genomics (TXG) provided 2023 revenue guidance that did not include the consensus, Street analyst seem unfazed.
- Cowen's Dan Brennan, who has an outperform rating, raised the stock's price target to $57 from $52 (23% upside based on Wednesday's close). He called the guidance conservative.
- Stifel's Daniel Arias, who rates 10x Genomics (TXG) a buy, raised his target price to $57 from $53 (23% upside). He noted that the 12%-16% 2023 growth the company is eying is "a good starting point."
- Seeking Alpha's Quant Rating views 10x Genomics (TXG) as a hold.